Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
11/2000
11/15/2000EP1051431A1 Thrombin inhibitors
11/15/2000EP1051425A2 2-(PURIN-9-yl)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES
11/15/2000EP1051395A1 Hydroxamic and carboxylic acid derivatives
11/15/2000EP1051192A2 Methods for the prevention and treatment of fibrosis and sclerosis
11/15/2000EP1051173A1 Derivatives of 1,3,4-oxadiazolone
11/15/2000EP1051172A2 Method for treating copd
11/15/2000CN1273584A Imidazolyl-cyclic acetals
11/15/2000CN1273579A Anthranilic acid analogs
11/15/2000CN1058408C Nasitis powder and producing process thereof
11/15/2000CN1058401C Method for preparation Yanmei medicine
11/14/2000US6147275 Corticotropin releasing factor receptor 1-deficient mice
11/14/2000US6147250 Treating diseases mediated by vascular cell adhesion molecule-1, including cardiovascular and inflammatory diseases; succinobucol
11/14/2000US6147224 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
11/14/2000US6147109 Treating impotency; brain, cardiovascular, respiratory system and gastrointestinal disorders
11/14/2000US6147071 Tachykinin receptor antagonist
11/14/2000US6147050 5-lipoxygenase-activating protein II
11/14/2000US6146876 22025, a novel human cyclic nucleotide phosphodiesterase
11/14/2000US6146659 Method of administering liposomal encapsulated taxane
11/09/2000WO2000066754A1 Protein c derivatives
11/09/2000WO2000066739A2 Chlamydia antigens and corresponding dna fragments and uses thereof
11/09/2000WO2000066708A2 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
11/09/2000WO2000066631A1 SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ¿1?
11/09/2000WO2000066630A1 DNA ENCODING SNORF36a AND SNORF36b RECEPTORS
11/09/2000WO2000066584A1 1-AMINO TRIAZOLO¢4,3-a! QUINAZOLINE-5-ONES AND OR -5-THIONES INHIBITING PHOSPHODIESTERASE IV
11/09/2000WO2000066563A1 Imidazoline derivatives as alpha-1a adrenoceptor ligands
11/09/2000WO2000066559A1 Piperidine derivatives useful as ccr5 antagonists
11/09/2000WO2000066558A1 Piperazine derivatives useful as ccr5 antagonists
11/09/2000WO2000066522A1 Glucocorticoid receptor modulators
11/09/2000WO2000066151A1 Use of heparin-binding antagonists in the inhibition of bradykinin release
11/09/2000WO2000066148A1 Novel proteins
11/09/2000WO2000066144A2 Monthly doses of glycopeptide antibiotics for treatment of streptococcus pneumoniae infections
11/09/2000WO2000066135A1 Use of phyllanthus for targeted stimulation of the immune system
11/09/2000WO2000066134A1 Use of phyllanthus for treating chronically inflammatory and fibrotic processes
11/09/2000WO2000066123A1 Synergistic combination comprising roflumilast and a pde-3 inhibitor
11/09/2000WO2000066112A1 Cxcr-4 receptor antagonists - thrombopoietin mimetics
11/09/2000WO2000066107A2 Antimalarian agents for the treatment of asthma
11/09/2000WO2000066106A2 Use of benzodiazepines for treating autoimmune diseases induced by apoptosis
11/09/2000WO2000066104A2 Ace-2 inhibiting compounds and methods of use thereof
11/09/2000WO2000066094A2 Use of compounds with a nitrogen-oxygen heterocycle as anti-infectious agents
11/09/2000WO2000066086A1 Anti-inflammatory bioactive glass particulates
11/09/2000WO2000040235A3 Treatment of asthma with mek inhibitors
11/09/2000WO2000038718A3 Use of matrix metalloproteinase inhibitor together with an antineoplastic agents, optionally also together with radiation, in the treatment of neoplasia
11/09/2000WO2000037094A3 Therapeutic applications of flint polypeptides
11/09/2000WO2000032584A3 Nonsteroidal antiinflammatories
11/09/2000WO2000021509A3 Methods of treatment
11/09/2000WO2000010968A3 Novel aryl sulphonamide amino acid esters and analogues
11/09/2000CA2388658A1 1-amino triazolo[4,3-a]quinazolin-5-ones and or -5-thiones inhibiting phosphodiesterase iv
11/09/2000CA2373021A1 Chlamydia antigens and corresponding dna fragments and uses thereof
11/09/2000CA2372923A1 Dna encoding snorf36a and snorf36b receptors
11/09/2000CA2372790A1 Monthly doses for treatment of streptococcus pneumonia infections
11/09/2000CA2372387A1 Ace-2 inhibiting compounds and methods of use thereof
11/09/2000CA2372223A1 Use of phyllanthus for targeted stimulation of the immune system
11/09/2000CA2372220A1 Use of phyllanthus for treating chronically inflammatory and fibrotic processes
11/09/2000CA2372173A1 Glucocorticoid receptor modulators
11/09/2000CA2370821A1 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
11/09/2000CA2370587A1 Use of heparin-binding antagonists in the inhibition of bradykinin release
11/09/2000CA2370304A1 Specific antibodies and antibody fragments for tgf.beta.1
11/09/2000CA2369526A1 Use of compounds with a nitrogen-oxygen heterocycle as anti-infectious agents
11/09/2000CA2338799A1 Protein c derivatives
11/08/2000EP1050307A1 CCR4 antagonists in sepsis
11/08/2000EP1049773A1 Inhibition of cytokine production
11/08/2000EP1049770A1 Secreted proteins and polynucleotides encoding them
11/08/2000EP1049700A1 Chemokine receptor antagonists and methods of use therefor
11/08/2000EP1049695A1 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
11/08/2000EP1049694A1 Benzothiadiazoles and derivatives
11/08/2000EP1049693A1 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS $g(a) v?$g(b) 3? ANTAGONISTS
11/08/2000EP1049691A1 Substituted 5-(2,2-difluoro-1,3-benzodioxol-5-yl) cyclopentenopyridine derivative
11/08/2000EP1049676A1 4- aryl(piperidin-4-yl)] aminobenzamides which bind to the delta-opioid receptor
11/08/2000EP1049675A1 Chemokine receptor antagonists and methods of use therefor
11/08/2000EP1049662A1 Inhibitors of alpha4 mediated cell adhesion
11/08/2000EP1049488A1 METHOD OF AND COMPOSITIONS FOR IMMUNIZATION WITH THE $i(PSEUDOMONAS) V ANTIGEN
11/08/2000EP1049483A1 Method for treating inflammatory diseases using heat shock proteins
11/08/2000EP1049476A1 Pharmaceutical compositions for mucolysis and treatment of inflammation
11/08/2000EP1049471A1 Compositions and methods for treating atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoids
11/08/2000EP1049467A1 Celecoxib compositions
11/08/2000CN1272840A Novel vitamin D derivatives with cyclopropyl rings in lateral chains, its production method and intermediate and utilization thereof for producing medicaments
11/08/2000CN1058176C Compounded Chuanling Dingchuan capsule for asthma
11/08/2000CN1058172C Medicine for curing nasitis
11/08/2000CN1058150C Topical aromatic releasing compositions
11/07/2000US6143792 Treatment of sleep apnea syndrome
11/07/2000US6143775 Physical form of zafirlukast; asthma
11/07/2000US6143759 Tetrazoles
11/07/2000US6143751 Pyridine derivatives and pharmaceutical compositions containing them
11/07/2000US6143746 Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
11/07/2000US6143733 Drugs for central nervous system diseases such as parkinson's disease, alzheimer's disease, huntington chorea, amyotrophic lateral sclerosis and olivopontocerebellar degeneration, psychiatric diseases such as anxiety conditions, migraine
11/07/2000US6143521 Human bombesin receptor subtype-3sb
11/07/2000US6143329 Aqueous-based pharmaceutical composition
11/07/2000US6143279 Uridine 5'-diphosphate and analogs useful for treating lung diseases
11/07/2000CA2170485C Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agents and caffeine
11/02/2000WO2000065058A1 Method for down-regulating il5 activity
11/02/2000WO2000065027A2 Human gil-19/ae289 proteins and polynucleotides encoding same
11/02/2000WO2000064944A1 Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
11/02/2000WO2000064900A1 Pyrazolobenzodiazepines as cdk2 inhibitors
11/02/2000WO2000064874A2 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/02/2000WO2000064538A1 Products and methods for brachytherapy
11/02/2000WO2000064520A1 Powder inhaler for combined medicament
11/02/2000WO2000064486A2 Enzymatically activated polymeric drug conjugates
11/02/2000WO2000064485A2 Specifically targeted catalytic antagonists and uses thereof
11/02/2000WO2000064474A1 Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
11/02/2000WO2000064441A2 Compound for use as a medicament for treatment of disorders involving bronchocontraction